pSivida signs Agreement with ITOCHU to Developand Commercialize...

pSivida signs Agreement with ITOCHU to Develop
and Commercialize Products in Japan & Asia
Global nanotechnology company pSivida Limited (ASX: PSD), is pleased to announce that it has
signed an Agreement with ITOCHU Corporation, one of the world’s largest companies, for the
development of commercial opportunities and products for BioSiliconTM in Japan and other
significant markets in Asia.
ITOCHU has an annual turnover of ¥9,517 billion (US$87.3 billion), with offices in over 80 countries
managing a range of businesses including consumer and retail products, IT, natural resources and
financial services.
ITOCHU’s strategic growth area is in the field of innovative technology with emphasis in Life
Sciences, Environment, Materials & Processing, Nanotechnology and Healthcare. The new
relationship with pSivida is expected to underpin new product development in the above areas. In
recent years, ITOCHU has successfully created a network in the healthcare industry through direct
investment in Biotechnology Ventures, Intellectual Property commercialisation and investment in
Life Science Funds. For a summary of recent investments refer to the Notes to Editors section.
Under the Agreement, pSivida and ITOCHU will jointly identify, establish and pursue various
opportunities to commercialize and develop products for pSivida’s BioSilicon technology platform in
Asia.